We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to start...
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
biotechs: Archive
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
by Zacks Equity Research
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
JNJPositive Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe
by Zacks Equity Research
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
NVSPositive Net Change PFENegative Net Change BPMCNegative Net Change DCPHPositive Net Change
biotechs
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
by Zacks Equity Research
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
BIIBNegative Net Change RHHBYPositive Net Change BMYPositive Net Change PRTANegative Net Change
biotechs pharmaceuticals
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
BMYPositive Net Change PFENegative Net Change MRKNo Net Change CLVSNegative Net Change
biotechs
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
BEAMNegative Net Change SRPTPositive Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
RHHBYPositive Net Change SGENPositive Net Change TAKNegative Net Change GMABPositive Net Change
biotechs
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx
by Zacks Equity Research
The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.
RHHBYPositive Net Change BMYPositive Net Change BAYRYPositive Net Change EXELNegative Net Change
biotechs pharmaceuticals
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
BEAMNegative Net Change SRPTPositive Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
by Zacks Equity Research
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
RHHBYPositive Net Change BMYPositive Net Change PFENegative Net Change EPZMNegative Net Change
biotechs
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
by Zacks Equity Research
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development
by Zacks Equity Research
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
AZNPositive Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs vaccines
Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
SNYPositive Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs messenger-rna
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
BMYPositive Net Change PFENegative Net Change INCYNegative Net Change ABBVPositive Net Change
biotechs pharmaceuticals
Find 'Strong Buy' Stocks for October and Beyond with this Screener
by Benjamin Rains
Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to start...
JPMPositive Net Change ALKSNegative Net Change SBPositive Net Change
biotechs transportation
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
JPMPositive Net Change NKEPositive Net Change PFENegative Net Change DALNegative Net Change COSTPositive Net Change MRNANegative Net Change FDXPositive Net Change
airlines biotechs communications finance pharmaceuticals retail transportation
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
JNJPositive Net Change AMGNPositive Net Change ABBVPositive Net Change ALPNNegative Net Change IMABNegative Net Change BVSNegative Net Change
biotechs pharmaceuticals
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
REGNNegative Net Change NVSPositive Net Change BMYPositive Net Change BLUEPositive Net Change
biotechs medical
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
BIIBNegative Net Change RHHBYPositive Net Change LLYPositive Net Change PRTANegative Net Change SAVANegative Net Change
biotechs
4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio
by Zacks Equity Research
Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.
REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechs pharmaceuticals
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
by Zacks Equity Research
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
REGNNegative Net Change VRTXNegative Net Change HZNPNegative Net Change FBIONo Net Change
biotechs
Why CRISPR Therapeutics (CRSP) Stock is Falling Today
by Madeleine Johnson
Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?
CRSPNegative Net Change
biotechs gene-editing
Amgen (AMGN) Reports New Data From Lumakras Combo Study
by Zacks Equity Research
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
REGNNegative Net Change AMGNPositive Net Change VRTXNegative Net Change HZNPNegative Net Change
biotechs medical
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
by Zacks Equity Research
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
BMYPositive Net Change BLUEPositive Net Change ALLONegative Net Change SWTXNegative Net Change
biotechs
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
RARENegative Net Change VTVTNegative Net Change EVLONegative Net Change GRTSNegative Net Change
biotechs
Bristol Myers (BMY) UC Candidate Fails in Phase II Study
by Zacks Equity Research
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
RHHBYPositive Net Change BMYPositive Net Change MRKNo Net Change AMGNPositive Net Change
biotechs pharmaceuticals